Jens-Peter Marschner

Title: Jens-Peter Marschner: Innovator in Cancer Therapy

Introduction

Jens-Peter Marschner is a notable inventor based in Seeheim-Jugenheim, Germany. He has made significant contributions to the field of cancer therapy, particularly through his innovative approaches to antibody treatments. His work focuses on developing effective therapies for challenging conditions such as Hodgkin lymphoma.

Latest Patents

Marschner holds a patent for a groundbreaking combination therapy. This patent, titled "Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy," describes a novel approach that combines a multifunctional antibody targeting CD30 and CD16A with an anti-PD-1 antibody. This combination aims to enhance treatment efficacy for tumors, especially Hodgkin lymphoma. He has 1 patent to his name.

Career Highlights

Jens-Peter Marschner is currently associated with Affimed GmbH, a company known for its innovative cancer immunotherapy solutions. His role at Affimed has allowed him to contribute to the development of cutting-edge therapies that leverage the immune system to combat cancer.

Collaborations

Throughout his career, Marschner has collaborated with esteemed colleagues, including Martin Treder and Uwe Reusch. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic strategies.

Conclusion

Jens-Peter Marschner's work exemplifies the innovative spirit in the field of cancer therapy. His contributions, particularly in antibody combination therapies, hold promise for improving treatment outcomes for patients with Hodgkin lymphoma.